July 7, 2017
Once again, Entasis Therapeutics has retained The Chase Group to build clinical/medical support for their CMO, Dr. Robin Isaacs. The Chase Group placed Dr. Robin Isaacs in his role and look forward to our continued partnership.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Their deep pipeline of novel clinical and pre-clinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
